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Abstract
Recombinant human erythropoietin
(rHuEPO) is available for correcting anemia.
PDpoetin, a new brand of rHuEPO, has been
certified by Food and Drug Department of
Ministry of Health and Medical Education of
Iran for clinical use in patients with chronic kid-
ney disease. We conducted this post-marketing
survey to further evaluate the safety and effica-
cy of PDpoetin for management of anemia in
patients on maintenance hemodialysis.
Patients from 4 centers in Iran were enrolled for
this multicenter, open-label, uncontrolled phase
IV clinical trial. Changes in blood chemistry,
hemoglobin and hematocrit levels, renal func-
tion, and other characteristics of the patients
were recorded for 4 months; 501 of the patients
recruited, completed this study. Mean age of the
patients was 50.9 (±16.2) years. 48.7% of
patients were female. Mean of the hemoglobin
value in all of the 4 centers was 9.29 (±1.43)
g/dL at beginning of the study and reached 10.96
(±2.23) g/dL after 4 months and showed signif-
icant increase overall (P<0.001). PDpoetin dose
was stable at 50-100 U/kg thrice weekly.
Hemorheologic disturbancesand changes in
blood electrolytes was not observed. No case of
immunological reactions to PDpoetin was
observed. Our study, therefore, showed that
PDpoetin has significantly raised the level of
hemoglobin in the hemodialysis patients (about
1.7±0.6 g/dL). Anemia were successfully cor-
rected in 49% of patients under study. Use of
this biosimilar was shown to be safe and effec-
tive for the maintenance of hemoglobin in
patients on maintenance hemodialysis. 
Introduction
Anemia is one of the adverse outcomes in
some conditions including End-Stage Renal
Disease (ESRD).1 There are many different
causes for anemia in patients on maintenance
hemodialysis, among which lack of folate and
B12 vitamin, gastrointestinal bleeding, iron
deficiency, serious inflammations and erythro-
poietin deficiency are of profound impor-
tance.2,3 When renal function is significantly
impaired or if there is no other possible cause
for anemia other than chronic kidney disease,
erythropoietin deficiency should be considered
as underlying cause of anemia. In such cases
treatment with erythropoiesis-stimulating
agents (ESAs) should be considered. If remain
untreated, anemia can drastically impair the
patient’s quality of life and lead to cardiac com-
plications.4-8 Some of associated cardiovascu-
lar complications due to anemia, such as left
ventricular hypertrophy and fibrosis, may be
irreversible.9 Therefore, prompt intervention
to correct hemoglobin level should be consid-
ered. ESAs such as erythropoietin are amongst
the most widely used agents in correcting
renal anemia.7,10-15 The role of recombinant
human erythropoietin alpha, as an ESA, in the
correction and maintenance of hemoglobin
values in patients with ESRD,16 cancer associ-
ated anemia with low levels of endogenous ery-
thropoietin,17 and HIV positive patients under
cytotoxic treatment, has been widely studied
for correcting anemia in ESRD patients.18 In
patients on maintenance hemodialysis hemo-
globin levels must be maintained more than 11
g/dL and hematocrit values must be main-
tained above 33% according to the European
Best Practice Guidelines (EBPG) for the man-
agement of anemia in patients with chronic
kidney disease,19 or in the range of 11-12 g/dL
according to National Kidney Foundation-
Kidney Disease Outcome Quality Initiative
guidelines (NKF-KDOQI).20
PDpoetin is a brand of recombinant human
erythropoietin alpha produced in Iran by
Pooyesh Darou pharmaceuticals.21 This drug
has successfully passed clinical trial phases I-
III;21,22 it has been approved by Food and Drug
Department of Ministry of Health and Medical
Education of Iran. In a controlled trial on its
immunogenicity and eliciting anti-rHuEPO
antibody, it has been shown that while admin-
istered subcutaneously, there is no significant
difference between the immunogenicity levels
of PDpoetin and Eprex (Janssen, Australia),
another well-known and widely used brand of
rHuEPO.23 The aim of this study is to scruti-
nize effectiveness and possible side effects of
PDpoetin in a post marketing surveillance
study.
Materials and MethodsStudy design
In the current multicenter, open-label,
uncontrolled clinical trial 501 patients receiv-
ing PDpoetin in daily practice from different
centers around Iran − namely Qom, Sari,
Tehran, and Mashhad − were enrolled from the
February 2011 since the July, 2011. Each
patient received 50-100 IU/kg of PDpoetin, 3
times weekly subcutaneously. If a patient did
not respond to initial dose within 4 weeks,
doses doubled for each administration. When
the ferritin levels was <100 ng/mL or the TSAT
was <20%, 100 mg of iron over each of the next
10 hemodialysis sessions and then every 2
weeks thereafter was administered intra-
venously. When subsequent iron parameters
remained below these values, a repeat loading
of 100 mg after the next 5 hemodialysis ses-
sions was given.
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Recombinant human erythropoietinand other medications
The rHuEPO provided as PDpoetin by
Pouyesh Darou Pharmaceuticals, Islamic
republic of Iran produced in the Chinese ham-
ster ovary (CHO) cells. The rHuEPO prepara-
tion was formulated in sterile buffered saline
solution containing 0.25% human serum albu-
min. Intravenous iron was given as Venofer
(Aspen Pharmacare, Australia).Inclusion criteria and exclusion criteria
Patients on maintenance hemodialysis at
least 3 months, Hct<30% or Hgb<11 g/dL, with-
out any serious inflammatory problems
(CRP<30 mg/L) and serum ferritin ≥100
ng/mL or TSAT ≥20% were included in this
study. Patients with BP ≥180/110, Hct ≥30% or
Hb level ≥11 g/dL, malignancies, cerebrovascu-
lar accident (CVA) and symptomatic Ischemic
Heart Disease (IHD) were excluded from this
study. Patients were excluded from the study
after enrollment and during the study if they
had seizures, receive renal transplantation or
blood transfusion, changed the modality of
dialysis, established systemic or vascular
access infection, vascular access thrombosis,
CVA, or uncontrolled hypertension and died.Ethical considerations
All patients signed informed consent form to
take part in this study. Helsinki Declaration
criteria and International Ethical Guidelines
for Biomedical Research involving Human
Subjects were respected.24Data collection
Data about clinical trial were gathered by
directly examining patients and recording the
changes in questionnaire by examining physi-
cian. Demographic information including age
and gender, and common clinical manifestations
and patient’s profile such as blood pressure (BP),
past medical history including ischemic heart
disease, CVA, malignancies, hypertension, and
blood chemistry parameters consisting of C-reac-
tive protein (CRP, qualitative method), monthly
iron parameters including ferritin, serum iron,
transferrin saturation (TSAT), basal and weekly
hematocrit-hemoglobin (Hct-Hgb) measure-
ments following subcutaneous PDpoetin admin-
istration were recorded carefully. Serum samples
were collected from poor responders to test for
anti-erythropoietin antibodies.  Statistical analysis
The results of the quantitative variables are
expressed as mean values ± standard devia-
tion (SD) and those of qualitative variables as
proportions. Statistical analysis was carried out
by SPSS software (version 16, IBM Corporation,
New York, USA). The effect of PDpoetin on vari-
ables was modeled using linear mixed model
analysis. P<0.05 was assumed to be significant.
Results Demographic information
Among those recruited for current study 501
patients completed the study and were included
in the analysis of data. 20 patients were lost to
follow up due to the following causes: 8 patients
were excluded because of at least one of the fol-
lowing causes like hypertension, infection and
deep vein thrombosis, 7 patients died of unre-
lated causes, and 5 patients changed their loca-
tion. The mean age of participants included in
data analysis in all centers was 50.9±16.2
years. 48.7% of patients were female.
Underlying causes of CKD in our study popula-
tion were dominated by hypertension by 30.5%
of all cases, followed by diabetes (26.4%). The
overall cause of renal insufficiency in our study
population is depicted in Figure 1.Dose of recombinant human erythropoietin
rHuEPO dose titration was done according
to previous studies.21,22 Briefly, patients
received 50 U of rHuEPO per kg bodyweight
per session at the beginning. The dosage was
then titrated according to the response,
increasing the dose by 50% when the increase
in Hct was <2% over a 2 to 4-week period, and
decreasing the dose by 25% when the increase
in Hct was >8% over a period of 4 weeks.
Hemoglobin and hematocritchanges
Our study showed about 1.7±0.6 g/dL of
hemoglobin increase in patients after 4
months of treatment with PDpoetin. The mean
hemoglobin level in our study was 9.29 (±1.43)
at the beginning of study and reached 10.9
(±2.23) at the end of the study (P<0.001)
(Figure 2). Mean hematocrit percent values
raised from 29.31 (±4.56) at the beginning of
study to 32.05 (±6.19) after 4 months of
PDpoetin administration (Figure 3; Table 1).
In 49% of our patients, anemia was corrected
according to the EBPG for the management of
anemia in patients with chronic renal failure
or NKF-KDOQI and reached more than 11 gr/dL
which is the target level of hemoglobin in the
current study.19,25-28 Iron metabolism was
maintained at acceptable level (Table 2).Hemorheologic disturbances
In the current study no blood electrolyte
change attributable to use of PDpoetin was
observed (Table 3). High blood pressure was
observed in 0.6% of patients, while 5.6% of
patients showed mild to moderate increases in
their blood pressure. Overall less than 1% of
our patients showed hemorheologic distur-
bances in mild to severe levels.  Safety
Other complications including vertigo,
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Figure 1. The underlying cause of chronic kidney disease in our study population.
Hypertension is the first known underlying cause of renal failure (30.5%) in patients in
the current study, followed by diabetes (26.4%), and glomerulonephritis (8.4%). About
3.5% of our patients with end-stage renal disease were suffering from both diabetes and
hypertension, while causes of renal failure in 31.2% of our patients were unknown.
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lethargy, fever, headache, myalgia, and fatigue
were observed with low incidence rate. Totally
97.8% of patients did not show any of the afore-
mentioned symptoms, 2% showed mild to mod-
erate adverse symptoms, and 0.2% of patients
showed severe forms of these adverse reac-
tions. Severe pain or other reactions like bruis-
ing or inflammation on the site of administra-
tion (injection) observed in 0.8% of patients. 
Anti-epoetin immunological reaction result-
ing in Pure Red Cell Aplasia (PRCA) was not
observed in the patients included in this study
after subcutaneous (s.c.) administration of
PDpoetin. Testing for anti-erythropoietin anti-
bodies in poor responders showed no case of
raising antibodies against PDpoetin. Most of
the patients had improper dietary habits and
many of the cases of treatment failure could be
attributed to these inappropriate dietary
habits. 
Discussion
Taking into account that this study is an
uncontrolled and multicenter trial in a country
with its especial culture, and many socio-eco-
nomical factors associated with treatment,
access to treatment, dietary habits, patient fol-
low-up and adherence to therapy must be con-
sidered in the interpretation of the data.
According to the EBPG for the management of
anemia in patients with chronic renal failure
or NFK-DOQI our results supported the effica-
cy of PDpoetin in the treatment of anemia in
patients on maintenance hemodialysis.19,20
During four months of treatment about half of
the patients reached the target level of 11 g/dL
of hemoglobin. However, the evidence from
current study is not enough to compare the
efficacy of the PDpoetin to other brands,
whereas many factors such as dietary habbits
and hemodialysis adequacy may affect the
results.29-31 These factors have been studied in
comparative studies of PDpoetin with Eprex
and the studies showed similar efficacy of
these two brands in hemoglobin maintenance
in hemodialysis patients.21,22
Article
Figure 3. Hematocrit changes after beginning of treatment with PDpoetin. Hct0, Hct1,
Hct2, Hct3 and Hct4 show respectively mean hematocrit percent values at the 0, 1, 2, 3,
and 4 months from beginning of the study.
Table 1. Hematological parameters presented as mean (± standard deviaton), n=501. 
Parameter Baseline Month 1 Month 2 Month 3 Month 4 P
Hb, g/dL 9.29 (±1.43) 9.66 (±1.48) 10.13 (±1.82) 10.4 (±2.07) 10.96 (±2.23) <0.001
Hct, % 29.31 (±4.56) 29.09 (±4.43) 30.61 (±5.55) 31.35 (±5.38) 32.05 (±6.19) <0.001
Reticulocytes, % 1.29 (±0.5) 2.86 (±1.1) 1.67 (±92) 1.36 (±1.13) 1.22 (±0.88) 0.014
WBCs ×103/mm3 7.55 (±5.9) 6.5 (±5.96) 6.7 (±5.64) 6.6 (±5.46) 6.14 (±2.22) 0.58
Hb, hemoglobin; Hct, hematocrit; WBCs, white blood cells.
Figure 2. Hemoglobin changes (g/dL) after beginning of treatment with PDpoetin. HB0,
HB1, HB2, HB3 and HB4 show respectively mean hemoglobin values at the 0, 1, 2, 3,
and 4 months from beginning of the study. 
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Results of the current study are consistent
with previous observations regarding immuno-
genicity of PDpoetin after s.c. administra-
tion.23 Administration of PDpoetin is via s.c.
route, while the recommended route of admin-
istration for ESAs in patients on dialysis is
through intravenous (i.v.) route. S.c. adminis-
tration is only recommended in patients not on
dialysis because of lack of readily available i.v.
access. Efficacy of PDpoetin in ESRD patients
on maintenance hemodialysis has been proven
in controlled trials. Data from current study is
consistent with results from previous stud-
ies.20,21 In terms of safety, our study proved the
safety of PDpoetin for clinical use in ESRD
patients on maintenance hemodialysis.
Conclusions
Our study confirmed the efficacy of
PDpoetin in treatment of anemia in patients
on maintenance hemodialysis. Also, our study
demonstrated that PDpoetin use is not associ-
ated with any significant side effects attributa-
ble to the use of this agent. 
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